Myasthenia Gravis, A Model of Organ-Specific Autoimmune Disease

1995 ◽  
Vol 8 (2) ◽  
pp. 139-143 ◽  
Author(s):  
Sonia Berrih-Aknin
2020 ◽  
pp. 145749692096433
Author(s):  
L. Liu ◽  
J. Zhang ◽  
G. Wang ◽  
C. Guo ◽  
Y. Chen ◽  
...  

Background and Aims: Although thymoma is inextricably linked to autoimmune disease, its best treatment method remains unclear. In this study, we sought to evaluate therapeutic effect of surgical resection of thymoma on non-myasthenia gravis autoimmune diseases. Materials and Methods: This was a retrospective study covering 32 patients with thymoma accompanied with non-myasthenia gravis autoimmune disease. The relationships between surgical treatment, thymoma pathological type, and prognosis of autoimmune diseases were analyzed from postoperative follow-up data. Results: In total, 32 patients in this study underwent surgical treatment. The mean age of the patients was 51.7 years. By the last follow-up, 2 patients had died, while the other 30 patients showed no sign of tumor recurrence and metastasis. According to the postoperative follow-up data, 22 patients (68.75%) showed improvement or even complete recovery of autoimmune disease symptoms, 9 patients (28.13%) showed no significant change, and only 1 patient’s (3.12%) postoperative symptom was aggravated. Female patients and patients aged 50 and older were more likely to combine with non-organ-specific autoimmune diseases (p = 0.036, p = 0.017). Conclusion: In conclusion, this study presents that surgical treatment achieves a satisfactory prognosis for thymoma combined with non-myasthenia gravis autoimmune disease.


2003 ◽  
Vol 172 (1) ◽  
pp. 302-309 ◽  
Author(s):  
D. Sean Riminton ◽  
Rama Kandasamy ◽  
Danijela Dravec ◽  
Antony Basten ◽  
Alan G. Baxter

2013 ◽  
Vol 110 (7) ◽  
pp. 2599-2604 ◽  
Author(s):  
K. D. Mason ◽  
A. Lin ◽  
L. Robb ◽  
E. C. Josefsson ◽  
K. J. Henley ◽  
...  

2021 ◽  
Vol 230 ◽  
pp. 103989
Author(s):  
Maria Weigand ◽  
Stefanie M. Hauck ◽  
Cornelia A. Deeg ◽  
Roxane L. Degroote

2011 ◽  
Vol 41 (4) ◽  
pp. 952-962 ◽  
Author(s):  
Geoffrey L. Stephens ◽  
Bonnie Swerdlow ◽  
Ebony Benjamin ◽  
Anthony J. Coyle ◽  
Alison Humbles ◽  
...  

CHEST Journal ◽  
2006 ◽  
Vol 129 (1) ◽  
pp. 213 ◽  
Author(s):  
Surinder S. Birring ◽  
Ian D. Pavord

2011 ◽  
Vol 64 (3-4) ◽  
pp. 183-187 ◽  
Author(s):  
Ljiljana Todorovic-Djilas ◽  
Tijana Icin ◽  
Jovanka Novakovic-Paro ◽  
Ivana Bajkin

Introduction, Autoimmune diseases are chronic conditions initiated by the loss of immunological tolerance to self-antigens. They constitute heterogeneous group of disorders, in which multiple alterations in the immune system result in a spectrum of syndromes that either target specific organs or affect the body systematically. Recent epidemiological studies have shown a possible shift of one autoimmune disease to another or the fact that more than one autoimmune disease may coexist in a single patient or in the same family. Numerous autoimmune diseases have been shown to coexist frequently with thyroid autoimmune diseases. Autoimmune thyroid disease and other organ specific non-endocrine autoimmune diseases. This part of the study reviews the prevalence of autoimmune thyroid disease coexisting with: pernicious anaemia, vitiligo, celiac disease, autoimmune liver disease, miastenia gravis, alopecia areata and sclerosis multiplex, and several recommendations for screening have been given. Autoimmune thyroid disease and other organ non-specific non-endocrine autoimmune diseases. Special attention is given to the correlation between autoimmune thyroid disease and rheumatoid arthritis, systemic lupus erythematosus, syndrome Sj?gren, systemic sclerosis and mixed connective tissue disease. Conclusions. Screening for autoimmune thyroid diseases should be recommended in everyday clinical practice, in patients with primary organ-specific or organ non-specific autoimmune disease. Other?wise, in patients with primary thyroid autoimmune disease, there is no good reason of seeking for all other autoimmune diseases, although these patients have a greater risk of developing other autoimmune disease. Economic aspects of medicine require further analyzing of these data, from cost/benefit point of view to justified either mandatory screening or medical practitioner judgment.


2005 ◽  
Vol 175 (11) ◽  
pp. 7135-7142 ◽  
Author(s):  
Richard J. DiPaolo ◽  
Deborah D. Glass ◽  
Karen E. Bijwaard ◽  
Ethan M. Shevach

Sign in / Sign up

Export Citation Format

Share Document